MANDATED PRESCRIPTION DRUG MONITORING PROGRAMS AND CHANGES IN ADOLESCENT INJECTION DRUG USE

Purpose: Prescription opioid misuse among adolescents remains an ongoing public health problem and is a risk factor for injection drug use (IOU), but few studies have evaluated strategies for preventing adolescent initiation of IOU. To reduce the prescription opioid supply, almost all states have pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of adolescent health 2020-02, Vol.66 (2S), p.S7
Hauptverfasser: Earlywine, Joel J, Hadland, Scott E, Raifman, Julia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2S
container_start_page S7
container_title Journal of adolescent health
container_volume 66
creator Earlywine, Joel J
Hadland, Scott E
Raifman, Julia
description Purpose: Prescription opioid misuse among adolescents remains an ongoing public health problem and is a risk factor for injection drug use (IOU), but few studies have evaluated strategies for preventing adolescent initiation of IOU. To reduce the prescription opioid supply, almost all states have prescription drug monitoring programs (PDMPs). Many states mandate that clinicians use the POMP before prescribing any controlled substances. The extent to which these 'POMP mandates' might protect against substance use and IOU among adolescents is unknown. We sought to evaluate the relationship between state POMP mandates and adolescent IOU. Methods: We used biannual Youth Risk Behavioral Surveillance System (YRBSS) individual-level data representative of adolescents aged 17-18 years across 47 states from 1995 to 2017. Using a differencein-differences design, we evaluated changes in the percent of adolescents reporting lifetime IDU before and after POMP mandates in 18 states that implemented mandates prior to January 1, 2017, compared to changes in IDU over time in 29 states without POMP mandates. We estimated linear regression models controlling for individual age, sex, race/ethnicity, state, year, and state-level poverty with standard errors clustered by state and standard YRBSS survey weights. Sensitivity analyses examined whether any potential changes in adolescent IDU might have begun to occur prior to POMP mandates, as well as whether changes were sustained for at least two years beyond implementation. We used US Census Bureau data to estimate the number of adolescents who might have been prevented from initiating IDU if all states had implemented POMP mandates. Results: Among 331,025 students, 51.7% identified as male, 62.1% as non-Hispanic white, 17.4% as non-Hispanic black, 14.6% as Hispanic, and 5.9% as another race or ethnicity. Among all adolescents, 3.5% (95% confidence interval [0], 2.8 to 4.2%) reported IDU prior to POMP mandates. Baseline trends in IDU did not differ in states that did and did not mandate PDMPs (point estimate,
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2375485130</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2375485130</sourcerecordid><originalsourceid>FETCH-proquest_journals_23754851303</originalsourceid><addsrcrecordid>eNqNi7sKwjAARYMoWB__EHAuJE2fY2hjjNikpCkIDsWhDkWsNvb_zSC4Ot17OefOgIfTJPNxlgRz11EU-phk5yVYWdsjhOMYIw9cSioLalgBK83qXIvKCCVhoRsOSyWFUVpI7qDimpY1dDbMD1RyVkMhIS3Uyd2YNG4dWf47NzXbgMXterfd9ptrsNszkx_85zi8ps6-236YxodDbUCSKEwjTBD5z_oA5IA7fw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2375485130</pqid></control><display><type>article</type><title>MANDATED PRESCRIPTION DRUG MONITORING PROGRAMS AND CHANGES IN ADOLESCENT INJECTION DRUG USE</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Earlywine, Joel J ; Hadland, Scott E ; Raifman, Julia</creator><creatorcontrib>Earlywine, Joel J ; Hadland, Scott E ; Raifman, Julia</creatorcontrib><description>Purpose: Prescription opioid misuse among adolescents remains an ongoing public health problem and is a risk factor for injection drug use (IOU), but few studies have evaluated strategies for preventing adolescent initiation of IOU. To reduce the prescription opioid supply, almost all states have prescription drug monitoring programs (PDMPs). Many states mandate that clinicians use the POMP before prescribing any controlled substances. The extent to which these 'POMP mandates' might protect against substance use and IOU among adolescents is unknown. We sought to evaluate the relationship between state POMP mandates and adolescent IOU. Methods: We used biannual Youth Risk Behavioral Surveillance System (YRBSS) individual-level data representative of adolescents aged 17-18 years across 47 states from 1995 to 2017. Using a differencein-differences design, we evaluated changes in the percent of adolescents reporting lifetime IDU before and after POMP mandates in 18 states that implemented mandates prior to January 1, 2017, compared to changes in IDU over time in 29 states without POMP mandates. We estimated linear regression models controlling for individual age, sex, race/ethnicity, state, year, and state-level poverty with standard errors clustered by state and standard YRBSS survey weights. Sensitivity analyses examined whether any potential changes in adolescent IDU might have begun to occur prior to POMP mandates, as well as whether changes were sustained for at least two years beyond implementation. We used US Census Bureau data to estimate the number of adolescents who might have been prevented from initiating IDU if all states had implemented POMP mandates. Results: Among 331,025 students, 51.7% identified as male, 62.1% as non-Hispanic white, 17.4% as non-Hispanic black, 14.6% as Hispanic, and 5.9% as another race or ethnicity. Among all adolescents, 3.5% (95% confidence interval [0], 2.8 to 4.2%) reported IDU prior to POMP mandates. Baseline trends in IDU did not differ in states that did and did not mandate PDMPs (point estimate, &lt;0.001 ; 95% CI, -0.001 to 0.002). POMP mandates were associated with a 1.5 percentage point (95% CI, 0.6 to2.4 percentage-points) reduction in adolescent IDU, a relative reduction of 42.9% (95% CI, 17.1 to 68.6%). Sensitivity analyses were consistent with the main results. Declines in IDU did not precede POMP mandate implementation (point estimate, 0.005; 95% CI, -0.04 to 0.013 ). The effect of POMP mandates persisted at least two years beyond implementation, with an associated 1.5 percentage point reduction (95% CI, 0.5 to 2.5 percentage points) in IDU, indicating the effect of the laws persisted over time. Using US Census Bureau data on the population of 17-18 year-olds in 2017, this reduction translates into 128,195 (95% CI, 51,098 to 204,992) fewer adolescents initiating IDU if all states had implemented POMP mandates. Conclusions: POMP mandates were associated with a reduction in adolescent IDU, providing empirical evidence that POMP mandates may prevent adolescents from initiating IDU. Policymakers might consider POMP mandates as a potential strategy for preventing adolescent IDU.</description><identifier>ISSN: 1054-139X</identifier><identifier>EISSN: 1879-1972</identifier><language>eng</language><publisher>New York: Elsevier BV</publisher><subject>Adolescents ; Censuses ; Changes ; Drug abuse ; Ethnicity ; Health problems ; Implementation ; Individual differences ; Monitoring systems ; Narcotics ; Opioids ; Policy making ; Poverty ; Prescribing ; Prescription drugs ; Public health ; Race ; Risk behavior ; Risk factors ; Substance abuse ; Surveillance systems ; Teenagers ; Therapeutic drug monitoring</subject><ispartof>Journal of adolescent health, 2020-02, Vol.66 (2S), p.S7</ispartof><rights>Copyright Elsevier BV Feb 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,30998</link.rule.ids></links><search><creatorcontrib>Earlywine, Joel J</creatorcontrib><creatorcontrib>Hadland, Scott E</creatorcontrib><creatorcontrib>Raifman, Julia</creatorcontrib><title>MANDATED PRESCRIPTION DRUG MONITORING PROGRAMS AND CHANGES IN ADOLESCENT INJECTION DRUG USE</title><title>Journal of adolescent health</title><description>Purpose: Prescription opioid misuse among adolescents remains an ongoing public health problem and is a risk factor for injection drug use (IOU), but few studies have evaluated strategies for preventing adolescent initiation of IOU. To reduce the prescription opioid supply, almost all states have prescription drug monitoring programs (PDMPs). Many states mandate that clinicians use the POMP before prescribing any controlled substances. The extent to which these 'POMP mandates' might protect against substance use and IOU among adolescents is unknown. We sought to evaluate the relationship between state POMP mandates and adolescent IOU. Methods: We used biannual Youth Risk Behavioral Surveillance System (YRBSS) individual-level data representative of adolescents aged 17-18 years across 47 states from 1995 to 2017. Using a differencein-differences design, we evaluated changes in the percent of adolescents reporting lifetime IDU before and after POMP mandates in 18 states that implemented mandates prior to January 1, 2017, compared to changes in IDU over time in 29 states without POMP mandates. We estimated linear regression models controlling for individual age, sex, race/ethnicity, state, year, and state-level poverty with standard errors clustered by state and standard YRBSS survey weights. Sensitivity analyses examined whether any potential changes in adolescent IDU might have begun to occur prior to POMP mandates, as well as whether changes were sustained for at least two years beyond implementation. We used US Census Bureau data to estimate the number of adolescents who might have been prevented from initiating IDU if all states had implemented POMP mandates. Results: Among 331,025 students, 51.7% identified as male, 62.1% as non-Hispanic white, 17.4% as non-Hispanic black, 14.6% as Hispanic, and 5.9% as another race or ethnicity. Among all adolescents, 3.5% (95% confidence interval [0], 2.8 to 4.2%) reported IDU prior to POMP mandates. Baseline trends in IDU did not differ in states that did and did not mandate PDMPs (point estimate, &lt;0.001 ; 95% CI, -0.001 to 0.002). POMP mandates were associated with a 1.5 percentage point (95% CI, 0.6 to2.4 percentage-points) reduction in adolescent IDU, a relative reduction of 42.9% (95% CI, 17.1 to 68.6%). Sensitivity analyses were consistent with the main results. Declines in IDU did not precede POMP mandate implementation (point estimate, 0.005; 95% CI, -0.04 to 0.013 ). The effect of POMP mandates persisted at least two years beyond implementation, with an associated 1.5 percentage point reduction (95% CI, 0.5 to 2.5 percentage points) in IDU, indicating the effect of the laws persisted over time. Using US Census Bureau data on the population of 17-18 year-olds in 2017, this reduction translates into 128,195 (95% CI, 51,098 to 204,992) fewer adolescents initiating IDU if all states had implemented POMP mandates. Conclusions: POMP mandates were associated with a reduction in adolescent IDU, providing empirical evidence that POMP mandates may prevent adolescents from initiating IDU. Policymakers might consider POMP mandates as a potential strategy for preventing adolescent IDU.</description><subject>Adolescents</subject><subject>Censuses</subject><subject>Changes</subject><subject>Drug abuse</subject><subject>Ethnicity</subject><subject>Health problems</subject><subject>Implementation</subject><subject>Individual differences</subject><subject>Monitoring systems</subject><subject>Narcotics</subject><subject>Opioids</subject><subject>Policy making</subject><subject>Poverty</subject><subject>Prescribing</subject><subject>Prescription drugs</subject><subject>Public health</subject><subject>Race</subject><subject>Risk behavior</subject><subject>Risk factors</subject><subject>Substance abuse</subject><subject>Surveillance systems</subject><subject>Teenagers</subject><subject>Therapeutic drug monitoring</subject><issn>1054-139X</issn><issn>1879-1972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNqNi7sKwjAARYMoWB__EHAuJE2fY2hjjNikpCkIDsWhDkWsNvb_zSC4Ot17OefOgIfTJPNxlgRz11EU-phk5yVYWdsjhOMYIw9cSioLalgBK83qXIvKCCVhoRsOSyWFUVpI7qDimpY1dDbMD1RyVkMhIS3Uyd2YNG4dWf47NzXbgMXterfd9ptrsNszkx_85zi8ps6-236YxodDbUCSKEwjTBD5z_oA5IA7fw</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Earlywine, Joel J</creator><creator>Hadland, Scott E</creator><creator>Raifman, Julia</creator><general>Elsevier BV</general><scope>7QJ</scope><scope>7TS</scope></search><sort><creationdate>20200201</creationdate><title>MANDATED PRESCRIPTION DRUG MONITORING PROGRAMS AND CHANGES IN ADOLESCENT INJECTION DRUG USE</title><author>Earlywine, Joel J ; Hadland, Scott E ; Raifman, Julia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_23754851303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescents</topic><topic>Censuses</topic><topic>Changes</topic><topic>Drug abuse</topic><topic>Ethnicity</topic><topic>Health problems</topic><topic>Implementation</topic><topic>Individual differences</topic><topic>Monitoring systems</topic><topic>Narcotics</topic><topic>Opioids</topic><topic>Policy making</topic><topic>Poverty</topic><topic>Prescribing</topic><topic>Prescription drugs</topic><topic>Public health</topic><topic>Race</topic><topic>Risk behavior</topic><topic>Risk factors</topic><topic>Substance abuse</topic><topic>Surveillance systems</topic><topic>Teenagers</topic><topic>Therapeutic drug monitoring</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Earlywine, Joel J</creatorcontrib><creatorcontrib>Hadland, Scott E</creatorcontrib><creatorcontrib>Raifman, Julia</creatorcontrib><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Physical Education Index</collection><jtitle>Journal of adolescent health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Earlywine, Joel J</au><au>Hadland, Scott E</au><au>Raifman, Julia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MANDATED PRESCRIPTION DRUG MONITORING PROGRAMS AND CHANGES IN ADOLESCENT INJECTION DRUG USE</atitle><jtitle>Journal of adolescent health</jtitle><date>2020-02-01</date><risdate>2020</risdate><volume>66</volume><issue>2S</issue><spage>S7</spage><pages>S7-</pages><issn>1054-139X</issn><eissn>1879-1972</eissn><abstract>Purpose: Prescription opioid misuse among adolescents remains an ongoing public health problem and is a risk factor for injection drug use (IOU), but few studies have evaluated strategies for preventing adolescent initiation of IOU. To reduce the prescription opioid supply, almost all states have prescription drug monitoring programs (PDMPs). Many states mandate that clinicians use the POMP before prescribing any controlled substances. The extent to which these 'POMP mandates' might protect against substance use and IOU among adolescents is unknown. We sought to evaluate the relationship between state POMP mandates and adolescent IOU. Methods: We used biannual Youth Risk Behavioral Surveillance System (YRBSS) individual-level data representative of adolescents aged 17-18 years across 47 states from 1995 to 2017. Using a differencein-differences design, we evaluated changes in the percent of adolescents reporting lifetime IDU before and after POMP mandates in 18 states that implemented mandates prior to January 1, 2017, compared to changes in IDU over time in 29 states without POMP mandates. We estimated linear regression models controlling for individual age, sex, race/ethnicity, state, year, and state-level poverty with standard errors clustered by state and standard YRBSS survey weights. Sensitivity analyses examined whether any potential changes in adolescent IDU might have begun to occur prior to POMP mandates, as well as whether changes were sustained for at least two years beyond implementation. We used US Census Bureau data to estimate the number of adolescents who might have been prevented from initiating IDU if all states had implemented POMP mandates. Results: Among 331,025 students, 51.7% identified as male, 62.1% as non-Hispanic white, 17.4% as non-Hispanic black, 14.6% as Hispanic, and 5.9% as another race or ethnicity. Among all adolescents, 3.5% (95% confidence interval [0], 2.8 to 4.2%) reported IDU prior to POMP mandates. Baseline trends in IDU did not differ in states that did and did not mandate PDMPs (point estimate, &lt;0.001 ; 95% CI, -0.001 to 0.002). POMP mandates were associated with a 1.5 percentage point (95% CI, 0.6 to2.4 percentage-points) reduction in adolescent IDU, a relative reduction of 42.9% (95% CI, 17.1 to 68.6%). Sensitivity analyses were consistent with the main results. Declines in IDU did not precede POMP mandate implementation (point estimate, 0.005; 95% CI, -0.04 to 0.013 ). The effect of POMP mandates persisted at least two years beyond implementation, with an associated 1.5 percentage point reduction (95% CI, 0.5 to 2.5 percentage points) in IDU, indicating the effect of the laws persisted over time. Using US Census Bureau data on the population of 17-18 year-olds in 2017, this reduction translates into 128,195 (95% CI, 51,098 to 204,992) fewer adolescents initiating IDU if all states had implemented POMP mandates. Conclusions: POMP mandates were associated with a reduction in adolescent IDU, providing empirical evidence that POMP mandates may prevent adolescents from initiating IDU. Policymakers might consider POMP mandates as a potential strategy for preventing adolescent IDU.</abstract><cop>New York</cop><pub>Elsevier BV</pub></addata></record>
fulltext fulltext
identifier ISSN: 1054-139X
ispartof Journal of adolescent health, 2020-02, Vol.66 (2S), p.S7
issn 1054-139X
1879-1972
language eng
recordid cdi_proquest_journals_2375485130
source Applied Social Sciences Index & Abstracts (ASSIA); ScienceDirect Journals (5 years ago - present)
subjects Adolescents
Censuses
Changes
Drug abuse
Ethnicity
Health problems
Implementation
Individual differences
Monitoring systems
Narcotics
Opioids
Policy making
Poverty
Prescribing
Prescription drugs
Public health
Race
Risk behavior
Risk factors
Substance abuse
Surveillance systems
Teenagers
Therapeutic drug monitoring
title MANDATED PRESCRIPTION DRUG MONITORING PROGRAMS AND CHANGES IN ADOLESCENT INJECTION DRUG USE
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T22%3A37%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MANDATED%20PRESCRIPTION%20DRUG%20MONITORING%20PROGRAMS%20AND%20CHANGES%20IN%20ADOLESCENT%20INJECTION%20DRUG%20USE&rft.jtitle=Journal%20of%20adolescent%20health&rft.au=Earlywine,%20Joel%20J&rft.date=2020-02-01&rft.volume=66&rft.issue=2S&rft.spage=S7&rft.pages=S7-&rft.issn=1054-139X&rft.eissn=1879-1972&rft_id=info:doi/&rft_dat=%3Cproquest%3E2375485130%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2375485130&rft_id=info:pmid/&rfr_iscdi=true